App-Quantinova.ai

Ixazomib plus Lenalidomide‐Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies

G. Cook - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Multiple Myeloma

Intratect

Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression‐Free Survival Post‐Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE‐MM3 Trial

M. Kaiser - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastrointestinal syndrome

Lenalidomide

Prevalence of Rh variant phenotypes and rate of immunisation in the haemoglobinopathy patient population in England

K. DeSay - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Methadone hydrochloride

Efficacy and safety of LentiGlobin gene therapy in patients with transfusion‐dependent β‐thalassaemia and non‐β0/β0 genotypes: Updated results from the completed phase 1/2 Northstar and ongoing phase 3 Northstar‐2 studies

J.B. Porter - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Transfusion‐dependent β‐thalassaemia

Plerixafor

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

T. Munir - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic Lymphocytic Leukemia

Idelalisib

Diffuse large B‐cell lymphoma remodels the fibroblastic reticular network that acquires aberrant immunosuppressive capabilities; implications for the regulation of anti‐tumor immunity in the immuno‐oncology era.

B. Apollonio - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Enhancer landscape in Chronic Lymphocytic Leukaemia upon BTK inhibition

A. Lambe - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Ibrutinib

Real‐World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

E. Poynton - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Methotrexate

HAVEN 2: Emicizumab Prophylaxis for Children with Haemophilia A with FVIII Inhibitors

G. Young - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Thrombotic microangiopathy

FVIII

Whole genome sequencing of patients with haematological, immune and haemostatic disorders reveals hundreds of new variants in the coding and non‐coding part of the genome causal of rare diseases

S. Sivapalaratnam - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Macrothrombocytopenia

N/A

Thrombotic thrombocytopenic purpura: demographic analysis of the UK TTP registry from 2009 to 2018

J.-S. Shin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Thrombotic thrombocytopenic purpura

Rituximab

A novel shear flow‐based assay to assess treatment response in congenital thrombotic thrombocytopenic purpura

F. Alwan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombotic thrombocytopenic purpura

thrombospondin-1

Parasite histones are associated with poor outcome in cerebral malaria

C. Moxon - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cerebral malaria

Heparin

Combining Sulfasalazine with Parthenolide to Prevent Chemoresistance in B Cell Precursor ALL

P. Diamanti - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Sulfasalazine

Automated data‐extraction and decision‐tree program to improve diagnostic accuracy in MDS

T. Coats - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

N/A

Using a Screening Technique to Identify New Combination Therapies with Potential to Improve Treatment of Paediatric Acute Myeloid Leukaemia

K. Lappin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

Cysteine Hydrochloride

Identification of signalling pathways regulated by KDM4A in MLL‐AF9 AML via a novel kinase activity screen

S. Patterson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Interleukin

The clinical validation and laboratory implementation of fragment analysis for the measurement of the FLT3‐ITD allelic ratio in patients with Acute Myeloid Leukaemia

C. Wilton - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

L-Tyrosine

Investigating the effects of parthenolide in Initiating Subpopulations in Childhood Leukaemia

R. Di Traglia - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Blinatumomab

Synergistic effects of FLT3 inhibition with sorafenib and adenosine monophosphate‐activated protein kinase (AMPK) activation observed in FLT3‐ITD+ AML cells in vitro

Y. Duvieusart - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Adenosine

Filters

45280 Abstracts